Hyperinsulinemia and type II diabetes are associated with an increased risk of developing colorectal tumors. We found previously that in intestinal cells, insulin or insulinlike growth factor-1 stimulates c-Myc and cyclin D1 protein expression through both Akt-dependent and Aktindependent mechanisms. The effect of Akt is attributed to the stimulation of c-Myc translation by mammalian target of rapamycin. However, Akt-independent stimulation was, associated with an increase in b-catenin (b-cat) in the nucleus and an increased association between b-cat and T-cell factor binding sites on the c-Myc promoter, detected by chromatin immunoprecipitation. In this study, we show that insulin stimulated the phosphorylation/ activation of p-21-activated protein kinase-1 (PAK-1) in an Akt-independent manner in vitro and in an in vivo hyperinsulinemic mouse model. Significantly, shRNA (small hairpin RNA)-mediated PAK-1 knockdown attenuated both basal and insulin-stimulated c-Myc and cyclin D1 expression, associated with a marked reduction in extracellular signal-regulated kinase activation and b-cat phosphorylation at Ser675. Furthermore, PAK-1 silencing led to a complete blockade of insulin-stimulated b-cat binding to the c-Myc promoter and cellular growth. Finally, inhibition of MEK, a downstream target of PAK-1, blocked insulin-stimulated nuclear b-cat accumulation and c-Myc expression. Our observations suggest that PAK-1 serves as an important linker between insulin and Wnt signaling pathways.
Introduction
Type II diabetes mellitus, previously known as noninsulin-dependent diabetes mellitus is classically characterized by insulin resistance, hyperinsulinemia and hyperglycemia. More than 90% of all diabetes cases in North America belong to this category, and it affects more than 150 million people worldwide (Lewin, 2008) . Epidemiological studies have shown a positive correlation between the metabolic syndrome, type II diabetes, hyperinsulinemia and the development of colorectal cancer (Giovannucci, 2007) . To explore the mechanisms underlying this correlation, studies have been carried out using rodent models, showing an effect of insulin on the formation of colorectal adenomas (Tran et al., 1996; Giovannucci, 2001; Elwing et al., 2006) .
Although most colorectal tumors are sporadic, a proportion of them are heritable. One of these syndromes is known as familial adenomatous polyposis. The locus of the familial adenomatous polyposi encodes the tumor suppressor gene APC (Adenomatous Polyposis Coli), which is mutated and is found to be inactivated in both patients with familial adenomatous polyposis and in many sporadic cases of colorectal cancer (Powell et al., 1992; Kinzler and Vogelstein, 1996; Clements et al., 2003; Clevers, 2004; Aguilera et al., 2006) . Under quiescent conditions, Axin, glycogen synthase kinase-3b (GSK-3b), casein kinase-Ia and APC form a complex with b-catenin (b-cat) that facilitates b-cat phosphorylation at Ser33, Ser37 and Thr41 by GSK-3b and casein kinase-Ia at Ser45, as well as its subsequent degradation by the ubiquitin-proteasome pathway (Aberle et al., 1997; Hinoi et al., 2000; Liu et al., 2002) .
b-Catenin is the key effector of the canonical Wnt signaling pathway. In the presence of Wnt ligands, activated Wnt receptors associate with Disheveled (Dvl) proteins, leading to the destabilization of the Axin-GSK-3b-APC complex and to the stabilization of b-cat. Free b-cat is then translocated into the nucleus to form a bipartite transcription factor with a member of the T-cell factor (TCF) family known as cat/TCF (Behrens et al., 1996; Molenaar et al., 1996) , which stimulates the transcription of Wnt or cat/TCF downstream target genes. A number of proto-oncogenes, such as c-Myc and cyclin D1, have been shown to serve as the Wnt downstream targets (He et al., 1998; Tetsu and McCormick, 1999) .
Extensive examinations have shown that the activity of cat/TCF can be stimulated by factors other than Wnt glycoproteins . For example, there are a number of reports that point to the insulin and insulinlike growth factor-1 (IGF-1) signaling pathways as stimulators of cat/TCF activity (Playford et al., 2000; Desbois-Mouthon et al., 2001) . In a previous study of ours, we were able to show that insulin stimulates the expression of the proto-oncogene, c-Myc, through a phosphoinositide 3-kinase (PI3K) and protein kinase B/Akt-dependent pathway involving mammalian target of rapamycin (mTOR) and a PI3K-dependent, but Aktindependent, mechanism. The latter pathway was associated with an increase in nuclear b-cat content and the stimulation of the association between b-cat and the TCF binding sites within the c-Myc gene promoter region . Therefore, we have concluded that insulin uses the effector of Wnt signaling, at least in part, in exerting its stimulatory effect on gene transcription . However, the mediators for this cross talk remain to be identified ( Figure 1a) .
The serine/threonine kinase P-21-activated protein kinase-1 (PAK-1) is known to be involved in the development and metastasis of tumors from various tissues, including the intestine (Carter et al., 2004; Ching et al., 2007; Akinmade et al., 2008) . PAK-1 was initially recognized as a downstream target of the Rho family GTPases, Rac1 and Cdc42, in regulating actin remodeling (Knaus and Bokoch, 1998; Zhou and Field, 2004; Arias-Romero and Chernoff, 2008) . PAK-1 can also be activated by Akt (Zhou et al., 2003) , or become directly phosphorylated/activated by PI3K (Tsakiridis et al., 1996) or phosphoinositide-dependent kinase isozyme-1 on Thr 423 (King et al., 2000) , without requiring Akt. In this study, we show that insulin stimulates the phosphorylation/activation of PAK-1 in both intestinal cancer and non-cancer cell lines, and in several mouse tissues, including the intestines. It seems that the activation is independent of Akt. Using a combination of chemical inhibitors of various signaling molecules and a Lentivirus-based small hairpin RNA (shRNA) knockdown approach, we identified that PAK-1 serves as an important mediator of the cross talk between insulin and cat/TCF in the regulation of c-Myc gene expression and cell proliferation.
Results

Insulin stimulates PAK-1 phosphorylation in intestinal cells
As illustrated schematically in Figure 1a , our previous observations prompted us to search for a PI3K-dependent, but Akt-independent, signaling pathway that mediates the cross talk between insulin/ IGF-1 and the Wnt signaling effector, cat/TCF. To assess whether PAK-1 serves as such a mediator, we first examined the effect of insulin on PAK-1 phosphorylation at its activation site, Thr423. The anti-PAK-1 antibody used in this study specifically recognizes PAK-1 but not PAK-2, whereas the anti-phospho-PAK-1 (pPAK-1) antibody recognizes both pPAK-1 (at Thr423) and pPAK-2 (at Thr402). In colon cancer cell lines HT29 (Figure 1b) and Caco-2 (data not shown), pPAK-2 was expressed constitutively, regardless of insulin treatment. In the rat intestinal non-cancer cell line IEC-6 and in the human breast cancer cell line MCF-7, pPAK-2 was not detected in samples without insulin treatment (Figure 1b ). Figure 1b also shows that in IEC-6, HT29 and MCF-7 cell lines, insulin treatment led to increased PAK-1 phosphorylation, detected 1 min after insulin treatment in the MCF-7 cell line and 5 min after insulin treatment in HT29 and IEC-6 cell lines. We then examined the effect of IGF-1, and observed that at either 50 or 100 nM, IGF-1 elicited PAK-1 phosphorylation in the HT29 cell line (Figure 1c) . A representative western blot in the HT29 cell line indicated that the stimulatory effect of IGF-1 on PAK-1 phosphorylation was sustained for up to 4 h. (Figure 1d) .
To examine the effect of insulin on PAK-1 phosphorylation in vivo, female adult FVB mice were injected with insulin intraperitoneally (0.2 U/kg). Ten minutes after the injection, mice were killed and various tissues were collected for western blot analysis. A representative blot shows that acute insulin treatment stimulated the phosphorylation of both Akt (Ser473) and PAK-1 in the liver, fat tissue, heart, as well as in the small and large intestines (Figure 1e ).
Insulin-stimulated PAK-1 phosphorylation is independent of Akt status both in vitro and in vivo We then investigated the involvement of Akt in insulinstimulated PAK-1 phosphorylation. To this end, HT29 cells were exposed to chronic insulin stimulation, a condition that mimics hyperinsulinemia-induced insulin resistance. As anticipated, after an overnight pretreatment of cells, we observed significantly attenuated Akt phosphorylation in response to further acute insulin treatment, indicative of these cells being in an insulin-resistant state (Figure 2a ). Interestingly, insulin was still able to stimulate PAK-1 phosphorylation in insulin pre-treated cells, indicating that p-Akt may not be involved in PAK-1 phosphorylation/activation. To verify this observation in a more physiological setting, we examined PAK-1 phosphorylation in the large intestinal tissue collected from low-fat diet (LFD)-and high-fat diet (HFD)-fed FVB mice. The mice on HFD had higher body weight and showed significantly reduced glucose tolerance compared with the LFD controls (data not shown). In addition, the HFD mice also had higher fasting plasma insulin levels compared with the LFD mice (0.52±0.02 ng/ml in HFD mice versus 0.44±0.006 ng/ml in LFD mice). Ten minutes after an intraperitoneal injection of insulin (0.2 U/Kg), mice were killed, and the cell lysates from the large intestines were prepared for the detection of Akt and PAK-1 phosphorylation by western blotting. As shown in Figure 2b , in the HFD-fed mice, acute insulin treatment elicited a much smaller effect on Akt phosphorylation, compared with that in the LFD-fed mice. In contrast, acute insulin treatment generated a more profound effect on PAK-1 phosphorylation in the HFD-fed mice compared with that in the LFD mice. These observations further suggest that insulin activation of PAK-1 in the intestinal cells is not affected by Akt activation.
Functional knockdown of PAK-1 reduces insulinstimulated proto-oncogene expression and insulin induced b-cat binding to human c-Myc gene promoter To examine whether PAK-1 has a role in insulinstimulated proto-oncogene expression, we first used a plasmid construct that expresses a Myc-tagged dominant negative (DN) form of human PAK-1 (K299R) (Tang et al., 1997 (Tang et al., , 1998 to inhibit PAK-1 function in the HT29 cell line. We also used and assessed the expression of a constitutively active form of PAK-1 (T423E). The DN PAK-1 mutant was initially shown to inhibit Ras-mediated transformation of Rat-1 fibroblasts and Schwann cells (Tang et al., 1997 (Tang et al., , 1998 , and has been used by several other studies that required functional knockdown of PAK-1 (Adam et al., 2000; Yoshii et al., 2001) . The constitutively active PAK-1 mutant was shown to stimulate Raf-1 phosphorylation at Ser338, thereby enhancing its mitochondrial localization .
Western blot analysis showed that when HT29 cells were transfected with mutant PAK-1 (K299R), we were able to detect the expression of PAK-1 (K299R) with the Myc-tag antibody (Figure 3a) . PAK-1 (K299R) expression in HT29 cells did not alter basal cyclin D1 or c-Myc expression, but was associated with B35 and B25% reduction in cyclin D1 and c-Myc protein expression in response to insulin treatment, respectively (Figure 3a) . In contrast, constitutively active PAK-1 (T423E) expression led to an increase in cyclin D1 and c-Myc expression, only in the absence of insulin stimulation (Figure 3b) .
We then examined whether the association of b-cat with the two transcriptional activating sites of the c-Myc gene promoter, TCF binding element 1 and 2 (TBE1 and 2), would be affected by PAK-1 (K299R) expression, using our previously described quantitative chromatin immunoprecipitation (qChIP) approach . Figure 3c shows the positions of TBE1 and TBE2, as well as the positions of control primers used in our qChIP analysis. As shown in Figure 3d , although insulin treatment stimulated a nearly four-fold increase in b-cat binding to TBE1 in both un-transfected and the vector transfected controls, only a 2.8-fold increase was detected in cells that were transfected with DN PAK-1 (K299R). Similarly, DN PAK-1 (K299R) expression resulted in an B20% reduction in insulin-stimulated b-cat binding to TBE2, compared with the controls (Figure 3d ).
Knockdown of the expression of PAK-1 blocks insulinstimulated c-Myc and cyclin D1 expression, and nuclear b-cat content Although the attenuating effect of PAK-1 (K299R) on insulin-stimulated c-Myc and cyclin D1 expression was statistically significant, the failure to elicit a more robust inhibition was possibly because of the low transfection efficiency of PAK-1 (K299R) in the HT29 cell line. On the basis of the data obtained from transfecting HT29 cells with an enhanced green fluorescent protein expressing control plasmid, we estimated that the transfection efficiency in this cell line by our method was approximately 12-15% (data not shown). As an alternative approach to verify the role of PAK-1, we used a Lentivirus-based delivery system to express a PAK-1 shRNA to knockdown the expression of PAK-1 in the HT29 cell line ( Figure 4a ). Infected cells were selected by puromycin treatment and detected by GFP expression (Figure 4b ), which is driven by the same promoter that drives the expression of the shRNA. As shown in Figure 4c , the expression of PAK-1 shRNA led to >70% reduction in PAK-1 protein expression, compared with cells expressing scrambled shRNA. Knockdown of the PAK-1 expression was associated with B50 and B65% reduction in c-Myc and cyclin D1 expression, respectively ( Figure 4c ). Furthermore, PAK-1 knockdown led to significantly reduced phospho-extracellular signal-regulated kinase1/2 (p-ERK1/2) expression in the presence and absence of insulin treatment. In addition, we show in this study for the first time that insulin stimulates b-cat phosphorylation at Ser675. The Ser675 residue on b-cat has recently been implicated in an increase in b-cat nuclear accumulation and transcriptional activity (Hino et al., 2005; Taurin et al., 2006) . We then assessed whether PAK-1 knockdown affects its own phosphorylation in response to insulin treatment and MEK inhibition. Figure 4d shows that although the expression level of p-PAK-2 in the HT29 cell line was not affected by PAK-1 shRNA, insulin treatment nor MEK inhibition, insulin-stimulated PAK-1 phosphorylation was attenuated by PAK-1 knockdown and was blocked by MEK inhibition. We have suggested that insulin cross talks with the Wnt pathway by increasing nuclear b-cat content Yi et al., 2008) . To further determine the role of PAK-1 in this cross talk, we examined nuclear b-cat levels post PAK-1 knockdown. A significant increase in nuclear b-cat content was detected in HT29 cells expressing the scrambled shRNA post insulin treatment (Figure 4e ). The basal level of nuclear b-cat in cells that express PAK-1 shRNA was reduced compared with that of the scrambled control. Although cells expressing PAK-1 shRNA responded to insulin with a slight increase in nuclear b-cat content, the level of the increase was significantly lower than that of the control cells (1.96-fold versus 1.3-fold, Figure 4e) .
We then applied qChIP to assess the effect of PAK-1 knockdown on the association of b-cat with the c-Myc gene promoter in the HT29 cell line. As presented in Cross talk between Wnt and insulin signaling J Sun et al
Figures 5a and b, insulin treatment significantly stimulated the association between b-cat and TBE1, or between b-cat and TBE-2, in both the mock-infected or the control shRNA expressing HT29 cells; the stimulation was not observed in the PAK-1 shRNA expressing HT29 cells. MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) assays were then performed to assess the effect of PAK-1 knockdown on cell growth. Consistent with our previous study Supplementary Figure 1. (e) HT29 cells were infected with the lentivirus expressing GIPZ-PAK-1 shRNAmir or GIPZ-scrambled for 72 h, followed by puromycin selection. Expressions of b-cat, histone H3 (nuclear protein marker as the loading control) in the nuclear fraction were detected by western blotting after 4 h of insulin (Ins) stimulation (n ¼ 4). Densitometrical data are expressed as mean±s.d. relative intensity (*Po0.05).
Cross talk between Wnt and insulin signaling J Sun et al were comparable with those that received no insulin treatment (Figure 5c ). Interestingly, the response to 4 h of insulin treatment in the PAK-1 shRNA expressing cells was still significant (Figure 5c ). This is consistent with the observation that 4 h of insulin treatment still stimulated c-Myc and cyclin D1 protein expression after PAK-1 knockdown (Figures 4c and 5d) . However, PAK-1 shRNA expressing cells were no longer responsive to insulin treatment after 24-48 h, because the expression of c-Myc and cyclin D1 was no longer detectable ( Figure 5d ). Collectively, these observations support our hypothesis that PAK-1 is among the mediators of insulin that stimulate Wnt target gene transcription. The effect of insulin on protein translation, however, is not directly affected by PAK-1 silencing.
MEK-ERK signaling pathway is involved in insulinstimulated c-Myc expression and nuclear b-cat expression
We have also observed that in PAK-1 shRNA expressing HT29 cells, the basal expression level of pERK was extremely low, whereas insulin-stimulated ERK phosphorylation was blocked completely (Figure 4c ). As MEK has been identified as one of the downstream targets of PAK-1 (Coles and Shaw, 2002; Eblen et al., 2002; Slack-Davis et al., 2003; Park et al., 2007) , we next examined whether the MEK-ERK signaling pathway participates in insulin-stimulated c-Myc expression and in b-cat nuclear content and function. PD98059 is a widely used inhibitor of MEK (Alessi et al., 1995; Dudley et al., 1995) . PD98059 pretreatment in HT29 cells did not affect phospho-GSK-3a or phospho-Akt levels in either the basal or insulin-stimulated condition (Figure 6a ). On the other hand, pretreatment with 20 or 50 mM PD98059 was sufficient enough to inhibit insulinstimulated ERK1/2 phosphorylation. This was correlated with a marked reduction in insulin-stimulated c-Myc protein expression (Figure 6a ). Furthermore, PD98059 significantly reduced nuclear b-cat expression levels in insulin-treated cells (Figure 6b) . We then performed qChIP in HT29 cells that were pretreated with either PI3K or MEK inhibitor. Similar to PAK-1 shRNA expressing cells, the increase in b-cat binding to TBE1 and TBE2 post insulin treatment was abolished in the HT29 cells that were pretreated with either PI3K or MEK inhibitor (Figures 6c and d) . These observations indicate that MEK-ERK functions as a downstream effector of PAK-1 in mediating the cross talk between insulin and the Wnt signaling effector, cat/TCF.
Discussion
Type II diabetes mellitus is associated with many other metabolic abnormalities, such as hyperinsulinemia, insulin resistance, dyslipidemia (elevated triglycerides and low HDL), as well as hypertension and an increased risk for atherosclerosis. Epidemiological studies have also documented an association between type II diabetes and a higher risk of colorectal cancer development (Chang and Ulrich, 2003; Ma et al., 2004; Elwing et al., 2006) . Although the importance of the Wnt signaling pathway in colorectal tumor formation has been well characterized (Ilyas et al., 1997; Bienz and Clevers, 2000; Clements et al., 2003) , there is increasing evidence that suggests a role for hyperinsulinemia in the development of colorectal and other types of tumors, and that this phenomenon may involve a molecular cross talk between the insulin and Wnt signaling pathways (Bustin, 2001; Desbois-Mouthon et al., 2001; Rochat et al., 2004; Sun and Jin, 2008; Yi et al., 2008) . Indeed, the major effector of the canonical Wnt signaling pathway, cat/TCF, has been shown in a number of cell lineages to be activated by factors other than the Wnt ligands, including insulin and IGF-1 . In hepatocellular carcinoma, insulin was found to trigger nuclear localization and the expression of b-cat (Desbois- Mouthon et al., 2001) . In intestinal endocrine L cells, we showed that insulin uses the same cis-and trans-elements that are used by the Wnt signaling pathway in stimulating proglucagon gene expression and in the production of the incretin hormone glucagon-like peptide-1 (Yi et al., 2008) . In intestinal nonendocrine cells, we found that insulin stimulates the expression of the Wnt target gene, c-Myc, at both the translational and transcriptional levels . The stimulatory effect of insulin on c-Myc translation was attributed to mTOR activation and involved Akt. The stimulation at the transcriptional level was PI3K dependent but Akt independent, and was associated with increased b-cat nuclear content and enhanced binding of b-cat to the human c-Myc gene promoter .
A report by Inoki et al. (2006) supports the concept that the Wnt signaling activation also stimulates gene expression at both the transcriptional and translation levels. The latter was also associated with the activation of mTOR and S6K1, mediated by the inactivation of GSK-3, but not requiring b-cat. In the absence of Wnt activation, GSK-3, in concert with AMP (adenosine monophosphate)-dependent protein kinase, catalyzed the pre-phosphorylation of Ser1341, phosphorylation of Ser1337 of TSC-2 and the increase in the GAP (GTPaseactivating protein) activity of the TSC1/2 (tuberous sclerosis complex) to inhibit mTOR (Inoki et al., 2006) . Therefore, both Wnt and insulin/IGF1 signaling resulted in mTOR activation and stimulation of cat/TCF activity to augment both the translation and the transcription of their common targets. However, before this investigation, the signaling mechanism of insulin/ IGF stimulation of cat/TCF-mediated gene transcription was not elucidated.
The Rho family small G-protein-activated target, PAK-1, has been implicated in both progression and metastasis of tumors. PAK-1 is overexpressed in hepatocellular carcinoma, especially in the more aggressive types, and has a role in enhancing metastasis (Ching et al., 2007) . The constitutive activation of PAK-1 rapidly induced breast cancer cell proliferation, and mutant kinase active T423E PAK-1 transgenic mice were found to develop hyperplasia in the mammary epithelium (Akinmade et al., 2008) . This hyperplasia was shown to respond to estrogen receptor activation, consistent with widely upregulated PAK-1 levels detected in human breast cancers (Akinmade et al., 2008) . Furthermore, PAK-1 was also shown to stimulate the expression of the Wnt target gene, cyclin D1 (He et al., 2008) .
Previous studies provided evidence of PAK-1 mediating signaling events in a PI3K-dependent but Aktindependent manner. However, none of these studies suggested the role of PAK-1 in mediating the cross talk between growth factors and Wnt signaling. In human bronchial epithelial cells, cigarette smoke-induced epidermal growth factor receptor-mediated activation of FRA-1 expression is carried out by the PI3K-(PAK-1)-(Raf)-MEK-ERK signaling cascade, without the participation of Akt (Li et al., 2005; Zhang et al., 2006) . In addition, Qiao et al. (2004) reported that IGF-1 stimulates the activity of the transcription factor RUNX2, through a PI3K-dependent but Akt-independent signaling pathway. Both Fra-1 and Runx2 are known downstream targets of the Wnt or cat/TCF signaling pathway (Mann et al., 1999; Dong et al., 2006) . In this study, we found that insulin stimulates PAK-1 phosphorylation/activation in multiple cancer cell lines and in mouse intestinal tissues on Thr423, a target residue of phosphoinositide-dependent kinase isozyme-1, hence bypassing Akt (King et al., 2000) . We have also found that PAK-1 knockdown significantly reduced insulin-stimulated c-Myc and cyclin D1 expression, as well as cell growth, and completely blocked the insulinstimulated interaction between b-cat and the c-Myc gene promoter. These observations suggested that PAK-1 is a mediator of Akt-independent insulin signaling for stimulating cat/TCF-dependent gene transcription. However, it should be pointed out that the involvement of signaling components upstream of PI3K, such as IRS-1 and IRS-2, in the activation of PAK-1 by insulin, requires further investigation. At this time, we cannot eliminate the possibility that insulin may exert this Akt-independent function through the IGF-1 receptor.
The p-21-activated protein kinase-1 has been shown to increase the association between MEK1 and Raf-1 by the phosphorylation of MEK1 at Thr292 (Eblen et al., 2002) . PAK-1 may also phosphorylate MEK1 at Ser298 to prime MEK1 for its subsequent activation by Raf-1 ( Coles and Shaw, 2002; Park et al., 2007) . We observed that PAK-1 knockdown significantly reduced both basal and insulin-stimulated ERK1/2 phosphorylation. Furthermore, we found that MEK inhibition reduced insulin-stimulated c-Myc expression and, similar to the effect of PAK-1 knockdown, abrogated the stimulatory effect of insulin on the association between b-cat and the c-Myc gene promoter. These observations suggest that the PAK-1-MEK-ERK axis is involved in insulinstimulated Wnt target gene transcription. By analyzing macrophages from PAK-1 À/À mice, Smith et al. (2008) have shown recently that PAK1 signals through ERK1/ 2 to regulate lamellipodial stability, indicating the in vivo physiological significance of the PAK-1-MEK-ERK axis. However, He et al. (2008) have shown a physical interaction between PAK-1 and b-cat. They found that the dominant negative PAK-1, the K299A mutant, blocked gastrin-induced b-cat translocation from the cell membrane to the nucleus, and that the association between b-cat and TCF-4 ( ¼ TCF7L2), suggesting the existence of other mechanisms that mediate the cross talk between hormone/growth factors and cat/TCF activity.
In this study, we observed that PAK-1 knockdown blocked the basal and insulin-stimulated b-cat phosphorylation at Ser675. Phosphorylation of b-cat at Ser675 by protein kinase A activation has been shown to stabilize b-cat by attenuating its ubiquitination and subsequent degradation (Hino et al., 2005) . Taurin et al. (2006) suggested that the Ser675 residue enhances TCF/ LEF transactivation by promoting the binding of b-cat to its transcriptional coactivator, the CREB (cAMP (cyclic adenosine monophosphate) response element binding-binding protein), CBP. Recently, Liu and Habener, (2008) reported that b-cat phosphorylation at Ser675 in pancreatic b cells can be activated by the incretin hormone glucagon-like peptide-1. To our knowledge, b-cat phosphorylation at Ser675 in response to insulin or IGF-1 has not been previously documented. As b-cat phosphorylation at Ser675 is important for its stimulatory effect on Wnt downstream target genes, further study is required to examine whether it is PAK-1 itself or a downstream effector that phosphorylates b-cat at Ser675.
We suggest that MEK-ERK signaling is among the downstream effectors of PAK-1 in stimulating the transcription of cat/TCF responsive genes, and this involves b-cat phosphorylation at Ser675. This is supported by two lines of evidence. First, PAK-1 knockdown resulted in a nearly complete loss of p-ERK1/2 expression, along with the inhibition of basal b-cat (Ser675) expression and the blockade of insulinstimulated b-cat (Ser675) expression (Figure 4c ). Second, MEK inhibition and PAK-1 knockdown generated comparable repressive effects on nuclear b-cat content and the binding of b-cat to c-Myc promoter (Figures 4c, d, 5a, . However, in the control shRNA expressing HT29 cells, MEK inhibition did not block the effect of insulin on b-cat phosphorylation (Figure 4c ), suggesting that when the PAK-1 expression level is high, more than one signaling pathways are involved in stimulating b-cat phosphorylation at Ser 675 in response to insulin treatment.
Our suggestion that MEK-ERK acts as a downstream effector of PAK-1 is consistent with a previous observation that group A PAKs (PAK-1, PAK-2 and PAK-3) are required for ERK activation and transformation by Ras (Tang et al., 1997) . Furthermore, MEK-1 and C-Raf have been shown to be direct substrates of PAK (King et al., 1998; Li et al., 2001; Sundberg-Smith et al., 2005; Park et al., 2007) . However, it should be pointed out that we also observed that PAK-1 phosphorylation can be blocked by MEK inhibition (Figure 4d ), indicating that either the MEK inhibitor used in this study has a certain nonspecific activity or the possibility of the existence of a positive feedback loop. This relationship deserves further investigation.
We have suggested that insulin stimulates c-Myc oncogene expression at both the translational and transcriptional levels Sun and Jin, 2008) . As illustrated in Figure 1a , the effect of PAK-1 is independent of Akt. Therefore, PAK-1 mediates the stimulatory effect of insulin on nuclear content and activity of b-cat, the effector of Wnt signaling, resulting in the activation of c-Myc expression at the transcriptional level. At the same time, the stimulation of translation by insulin, when the PAK-1 expression level was reduced in response to shRNA-mediated knockdown, likely accounts for the residual stimulation at 4 h of insulin treatment of c-Myc (and cyclin D1) protein expression ( Figure 4c ) and cell growth (Figure 5c ). However, the stimulatory effect of insulin on cell growth was blocked by shRNA-mediated PAK-1 knockdown after X12 h of treatment. It is important to note that PAK-1 was phosphorylated in response to insulin in vivo and that in both cultured cells and mice that were rendered insulin resistant by chronic hyperinsulinemia and HFD, respectively, in contrast to Akt, the stimulation of PAK-1 phosphorylation was not reduced. Although this phenomenon remains to be further explored, the apparent lack of resistance to some of the growth-promoting effects of insulin, in contrast to its metabolic pathways, may be relevant to the documented association of hyperinsulinemia/insulin resistance with cancer development in certain tissues.
In summary, we show here that insulin stimulates the phosphorylation/activation of PAK-1 in vitro and in 
Materials and methods
Materials
Tissue culture medium, fetal bovine serum and oligonucleotides were purchased from Invitrogen Life Technology (Burlington, ON, Canada). Insulin was provided by Novo Nordisk (Copenhagen, Denmark). The PI3K inhibitor LY294002 and the MEK inhibitor PD98059 were purchased from Calbiochem (EMD Biosciences, San Diego, CA, USA). Lentiviral shRNAmir gene knockdown system was obtained from Thermo Fisher Scientific (Huntsville, AL, USA). The three PAK-1 shRNAmir sequences are shown in Figure 4a .
Animals and diets
All procedures were conducted according to protocols and guidelines approved by the Toronto General Hospital Animal Care Committee. FVB mice at the age of 13 weeks were randomly placed on a LFD (5% kcal fat) or on a HFD (45% kcal fat, 15% fructose). The mice were housed at the Animal Care Facility of the Toronto General Hospital in a 12 h lightdark cycle.
Body weights and intraperitoneal glucose tolerance test
Body weights were monitored and recorded weekly. IPGTTs (intraperitoneal glucose tolerance tests) were carried out on the mice after 15 weeks on the different diets. After an overnight fast (1.5 g/kg body weight) glucose was administered by an intraperitoneal injection. A blood sample was collected from a tail vein at 0, 10, 20, 30, 60, 90 and 120 min after glucose administration, and blood glucose levels were measured using a Sure Step, One Touch Glucometer (Lifescan, Johnson & Johnson, Milpitas, CA, USA). For plasma insulin determinations, a blood sample (100 ml) was obtained from the tail vein at the 0-min time period. The plasma was separated by centrifugation at 4 1C and stored at -80 1C until assayed. It was assayed for insulin using a mouse insulin ELISA kit (Linco Research, St Charles, MO, USA).
Plasmids, DNA transfection, cell culture and MTT assay The dominant negative PAK-1 plasmid, the K299R mutant, and the vector control, were gifts from Dr Jefferey Field (Sells et al., 1997; Tang et al., 2000) . DNA transfection was performed using Lipofectamine (Invitrogen Life Technology) according to the manufacturer's instructions. The human colon cancer cell lines HT29 and Caco2, the human breast cancer cell line MCF-7 and the rat intestinal cell line IEC-6 were purchased from the ATCC (American Type Culture Collection, Manassas, VA, USA). They were maintained as per the instructions of the ATCC. The MTT assay was carried out as previously described by Wang et al. (2003) .
Antibodies, cell fractionation and fluorescence microscopy Antibodies for Akt, phospho-Akt (Ser473), phospho-GSK3a/b (Ser21/9), phospho-b-cat (Ser674), phospho-PAK-1/2 (Thr423/Thr402), PAK-1, histone H3 and b-actin were purchased from Cell Signaling Technology (Cedarlane, ON, Canada). The antibody for GSK-3 (clone 4G-1E) was purchased from Upstate Biotechnology (Lake Placid, NY, USA). Antibodies for b-cat, c-Myc, cyclin D1 and the horseradish peroxidase-conjugated secondary antibodies were obtained from Santa Cruz Biotechnology (Santa Cruz, CA, USA). Nuclear and cytosolic protein fractions were prepared as described by Olnes and Kurl (1994) . Fluorescence signal in HT29 cells that expressed lentiviral delivered GFP-shRNA was viewed using an Olympus IX71 microscope (Olympus, Center Valley, PA, USA).
qChIP Approximately 2 Â 10 7 cells were used for each qChIP assay (Yi et al., 2005) . After sonication of control or insulin-treated cells, anti-b-cat antibody was applied to precipitate sheared chromatin DNA that interacts with b-cat. In each assay, precipitated chromatin DNA was dissolved in 60 ml of TE buffer, and 2 ml of sample was collected each time for real-time PCR (Yi et al., 2005) . Experimental and control primers for the ChIP assay are presented in Table 1 .
Statistical analysis
All data are presented as mean±s.d. Statistical analysis was carried out by either Student's t-test or by one-way ANOVA (analysis of variance) when appropriate. Significance was assumed at a P-value of o0.05.
